DOCSLIB.ORG

EVOLUTION to the NEXT STEP - the NEEDS of the FUTURE? a Joint Meeting Between TOPRA and the European Medicines Agency

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
EVOLUTION to the NEXT STEP - the NEEDS of the FUTURE? a Joint Meeting Between TOPRA and the European Medicines Agency EVOLUTION TO THE NEXT STEP - THE NEEDS OF THE FUTURE? A joint meeting between TOPRA and the European Medicines Agency TOPRA – The Organisation for Professionals in Regulatory Affairs Reference: CA4/09 The European Medicines Agency - what will the Two-day future bring us and what do we need to know today? Conference Date: The 4th annual EMEA round-up of the year and look towards Tuesday 1st to the next year - a firm favorite with many European regulatory Wednesday 2nd affairs personnel as the key year end event to reflect on the December 2009 year gone by and to plan for the upcoming year. Venue: East Wintergarden, Who should attend? Conference working party Canary Wharf, London This conference will cover all the major ● Anthony Humphreys, Head of Sector, areas of medicines legislation covered by the Regulatory Affairs and Organisational Timings: European Medicines Agency. If you are working Support, Post-Authorisation Evaluation of 8.00 Registration at a Europe wide level then this meeting is a Medicines for Human Use, EMEA for 9.00 Start must for all levels of regulatory personnel. It ● Arielle North, Scientific Administrator, EMEA on 1st December will provide you with practical advice on the ● Agnès Saint Raymond, Head of Orphan working of the EMEA within the European 17.30 Close Drugs, Scientific Advice and Paediatric regulatory network. on 2nd December Medicines, EMEA Conference programme includes ● Tomas Salmonson, Vice Chair CHMP, Medical Products Agency (MPA), Sweden ● European Union future regulatory activity – The Pharmaceutical Package, European ● Peter Bachmann, European and International Commission update; EMEA Road map 2015; Affairs, BfArM, Germany HMA Strategy paper ● Beatrice Oberlé-Rolle, Drug Regulatory ● Pharmacovigilance and Risk Management Affairs, Nobel Biocare, Switzerland ● ● Working internationally Brenton E James, Consultant in Strategic Regulatory Affairs in Europe, UK ● Reacting and planning for change - EMEA restructuring ● Liz Gifford, Director, Global Regulatory Affairs, GlaxoSmithKline, UK ● Paediatrics - clinical studies ● Donna Mountfield, Associate Director of TOPRA/ ● Clinical Trials Regulatory Affairs, Chugai Pharma Europe, UK EMEA ● Variations * Supported by TOPRA staff 12hrs ● CHMP Lifelong learning * For more information Please note: there will be a drinks reception on the evening of the 1st December to facilitate networking please visit www.topra. For more information or a booking form, please visit www.topra.org/emea2009 org/lifelonglearning email: [email protected] tel: +44 (0) 20 7510 2560 fax: +44 (0) 20 7537 2003 web: www.topra.org TUESDAY 1ST DECEMBER 2009 WEDNESDAY 2ND DECEMBER 2009 09.00 Welcome and Introduction from Paolo Biffignandi, TOPRA 11.4 0 Hot Topics - Peter Arlett, Head of Sector Pharmacovigilance 08.30 Opening Remarks Chaired by President, VI.REL Pharma S.a.s., Italy and Thomas Lönngren, and Risk Management, EMEA Peter Bachmann, European and International Affairs, BfArM, Germany Executive Director, European Medicines Agency 12.00 Implementation of Development Safety Update Reports SESSION 5 Hilde Boone, Scientific Administrator, EMEA (DSURs) in Europe - Barry Arnold, EU Qualified Person for Paediatrics – clinical studies 13.15 Introduction: Background and future work sharing - Peter SESSION 1 Pharmacovigilance, AstraZeneca R & D, UK This session will review the type of clinical trials that are usually included Bachmann and Hilde Boone European Union: The latest information on future 12.20 EU Risk Management Plans (RMP) - Stella Blackburn, Risk Management Coordinator, EMEA in Paediatric Investigations Plans, discuss aspects related to study 14.05 Industry viewpoint on work sharing - Fiona Reekie, Director, regulatory activity for pharmaceuticals feasibility from the view of sponsors and agencies and give advice on the Johnson & Johnson Pharmaceuticals, UK 12.40 Speaker Panel with this sessions’ speakers In the near future significant developments proposed by the set-up and conduct of long-term safety monitoring in children. 14.15 Speaker Panel with this sessions’ speakers 13.00 L u n c h European Commission, the European Medicines Agency and the Chaired by 14.45 Tea and Coffee Heads of Human Medicines Agencies will be released and have a very Agnès Saint Raymond, Head of Orphan Drugs, Scientific Advice and important impact on all stakeholders involved in Medicinal Products. SESSION 3 Paediatric Medicines, EMEA This session includes an update on the Pharmaceutical Package, the Working internationally SESSION 8 EMEA Road Map to 2015 and the Heads of Medicines Agencies Angelika Joos, Director Regulatory Policy Europe, Merck Sharp & Dohme Committee for Medicinal Products for Human Use Strategy Paper. This session will explore working internationally with recent initiatives in (Europe) Inc, Belgium (CHMP) – achievements and challenges the areas of transatlantic cooperation, Bilateral agreements (Japan, US, 08.40 Overview of clinical studies in Paediatric Investigation Plans (PIPs) Chaired by Canada etc), Clusters and with specific examples such as GMP and GCP. This session will review the operation of the CHMP within the European Irene Sacristan-Sanchez, Deputy Head DG Enterprise and Industry, 09.00 Are Paediatric trials feasible? regulatory network. Subjects to be covered by key speakers from Chaired by Pharmaceuticals Unit, European Commission 09.20 How to establish long-term safety in children? Regulatory Agencies (including the CHMP Chair) include the CHMP's Emer Cooke, International Liaison Officer, EMEA Brenton James, Consultant in European Regulatory Affairs in Europe, UK 09.40 Speaker Panel with this sessions’ speakers current activities and workload, it's achievements and successes and Tomas Salmonson, Vice Chair CHMP, Medical Products Agency (MPA), Sweden the way it interacts with other key committees and stakeholders (e.g. 10.15 Tea and Coffee 09.20 Introduction to this session - Brenton James, Consultant in CAT, PDCO, SAGs). The session will include discussion on some of the 14.00 Bilateral agreements and clusters - Emer Cooke, International European Regulatory Affairs in Europe, UK hot topics associated with the Centralised Procedure (e.g. Rapporteur Liaison Officer, EMEA 09.25 The Pharmaceutical Package - Irene Sacristan-Sanchez, Deputy SESSION 6 selection, the contribution of peer review and SAGs, transparency) and 14.20 Inspections, GCP and clinical trials Head DG Enterprise and Industry, Pharmaceuticals Unit, Clinical Trials will discuss some of the challenges that face the CHMP in the future European Commission 14.40 GMP - Oliver Gross, Scientific Administrator, EMEA with the Centralised Procedure. An example of a successful Centralised This session will review the state and recent developments in relation to 09.45 The EMEA Road Map to 2015 - Noel Wathion, Head of unit 15.00 Speaker Panel with this sessions’ speakers Procedure will be presented by an industry speaker. the conduct of clinical trials across the EU. The achievements within the Patient Health Protection, EMEA 15.30 Tea and Coffee voluntary harmonisation procedure will be reviewed as well as general Chaired by 10.05 Heads of Medicines Agencies Strategy Paper - Marcus Müllner, observations in relation to safety reporting and issue assessment. Eric Abadie, Chair of CHMP, Agence Française de Sécurité Sanitaire des Division Manager, AGES PharmMed/Austrian Medicines and Produits de Santé (Afssaps), France Medical Devices Agency, Austria SESSION 4 Chaired by Reacting and planning for change – Liz Gifford, Director, Global Regulatory Affairs GlaxoSmithKline, UK 10.25 Speaker Panel with this sessions’ speakers and invited panellist: Beatrice Oberlé-Rolle, Drug Regulatory Affairs, Nobel Biocare, Switzerland EMEA restructuring 15.15 Introduction by the Chair of CHMP - Eric Abadie, Chair of Judith Creba, Head of EU Liaison and Policy, Novartis, 10.15 Introduction Switzerland will comment upon the presentations and all CHMP, Agence Française de Sécurité Sanitaire des Produits de This session will review the recent reorganisation of the EMEA, the 10.55 Clinical Trial Harmonisation - Hartmut Krafft, Head of sector, attendees are invited to ask questions of the speakers. Santé (Afssaps), France reasons for this and the impact on stakeholders such as Heads of clinical trials, Paul-Ehrlich-Institut (PEI), Germany 11.0 0 Coffee break Medicines Agencies (HMA) and the impact on resources and training. 15.30 CHMP Work Load – Anthony Humphreys, Head of Sector, 11.15 CTFG activities - Chantal Bélorgey, Head of Division on Regulatory Affairs and Organisational Support, Post- Chaired by Evaluation of Special Status Medicinal Products and Clinical Authorisation Evaluation of Medicines for Human Use, EMEA trials, Afssaps, France SESSION 2 Arielle North, Scientific Administrator, EMEA 15.50 Committees and Working Parties - Xavier Luria Oller, Head of Pharmacovigilance and Risk Management Pat O'Mahony, Chair of EMEA Management Board, Chief Executive 11. 35 Industry observations Sector, Safety and Efficacy of Medicines, EMEA This session will cover new regulatory developments within the area Officer of IMB, Ireland 11.45 Tranparency of Clinical Trials 16.10 Special Projects - Eric Abadie, Chair of CHMP, Agence Française of Pharmacovigilance. Topics to be covered in this session include 16.00 EMEA Reorganisation - Patrick Le Courtois, Head of Unit, 12.15 L u n c h de Sécurité Sanitaire des Produits de Santé (Afssaps), France updates on topics such as ICH and CIOMS, the implementation of the Human Medicines Development
Load more

Recommended publications
  • Media Guide Template
    MOST CHAMPIONSHIP TITLES T O Following are the records for championships achieved in all of the five major events constituting U R I N the U.S. championships since 1881. (Active players are in bold.) N F A O M E MOST TOTAL TITLES, ALL EVENTS N T MEN Name No. Years (first to last title) 1. Bill Tilden 16 1913-29 F G A 2. Richard Sears 13 1881-87 R C O I L T3. Bob Bryan 8 2003-12 U I T N T3. John McEnroe 8 1979-89 Y D & T3. Neale Fraser 8 1957-60 S T3. Billy Talbert 8 1942-48 T3. George M. Lott Jr. 8 1928-34 T8. Jack Kramer 7 1940-47 T8. Vincent Richards 7 1918-26 T8. Bill Larned 7 1901-11 A E C V T T8. Holcombe Ward 7 1899-1906 E I N V T I T S I OPEN ERA E & T1. Bob Bryan 8 2003-12 S T1. John McEnroe 8 1979-89 T3. Todd Woodbridge 6 1990-2003 T3. Jimmy Connors 6 1974-83 T5. Roger Federer 5 2004-08 T5. Max Mirnyi 5 1998-2013 H I T5. Pete Sampras 5 1990-2002 S T T5. Marty Riessen 5 1969-80 O R Y C H A P M A P S I T O N S R S E T C A O T I R S D T I S C S & R P E L C A O Y R E D R Bill Tilden John McEnroe S * All Open Era records include only titles won in 1968 and beyond 169 WOMEN Name No.
    [Show full text]
  • Welcome to the 17Th International Conference on Liquid and Amorphous Metals!
    L A M – 1 7 Lyon, 26-30 August 2019 17th International Conference C T S on Liquid and Amorphous Metals T R A A B S 1 https://lam‐17.sciencesconf.org 2 https://lam‐17.sciencesconf.org Welcome to the 17th International Conference on Liquid and Amorphous Metals! The 17th International Conference on Liquids and Amorphous Metals in Lyon, August 26‐30, 2019, continues a series of meetings held every three years, most recently in Beijing, China (2013), and in Bonn, Germany (2016). In 2019, LAM‐17 is hosted jointly by the Institut Lumière Matière (ILM), University of Lyon 1, INSA and CNRS in Lyon. The aim of LAM conferences is to discuss new advances and future directions in the field of liquid and amorphous metals, by employing theoretical and simulations studies, laboratory techniques and large scale facilities such as synchrotrons and free electron lasers. The 17th edition will also include presentations on non‐metallic materials, such as molecular glasses, polymers and colloids in order to encourage the interdisciplinary among different disordered materials fields. The scientific program of LAM‐17 consists of plenary sessions, parallel oral sessions with invited keynotes and contributed presentations, as well as poster sessions. Presenters were invited or selected based on their abstract submissions by the International Advisory and Program Committees and the local organizing committee. The two best posters presented by students will be awarded with the possibility to perform a short term visit in a partner laboratory. The welcome cocktail on Monday, August 26th, at Villemanzy in the heart of the Lyon, is a first opportunity for conference participants to know each other and to network.
    [Show full text]
  • Official Directory of the European Union
    ISSN 1831-6271 Regularly updated electronic version FY-WW-12-001-EN-C in 23 languages whoiswho.europa.eu EUROPEAN UNION EUROPEAN UNION Online services offered by the Publications Office eur-lex.europa.eu • EU law bookshop.europa.eu • EU publications OFFICIAL DIRECTORY ted.europa.eu • Public procurement 2012 cordis.europa.eu • Research and development EN OF THE EUROPEAN UNION BELGIQUE/BELGIË • БЪЛГАРИЯ • ČESKÁ REPUBLIKA • DANMARK • DEUTSCHLAND • EESTI • ΕΛΛΑΔΑ • ESPAÑA • FRANCE • ÉIRE/IRELAND • ITALIA • ΚΥΠΡΟΣ/KIBRIS • LATVIJA • LIETUVA • LUXEMBOURG • MAGYARORSZÁG • MALTA • NEDERLAND • ÖSTERREICH • POLSKA • PORTUGAL • ROMÂNIA • SLOVENIJA • SLOVENSKO • SUOMI/FINLAND • SVERIGE • UNITED KINGDOM • BELGIQUE/BELGIË • БЪЛГАРИЯ • ČESKÁ REPUBLIKA • DANMARK • DEUTSCHLAND • EESTI • ΕΛΛΑ∆Α • ESPAÑA • FRANCE • ÉIRE/IRELAND • ITALIA • ΚΥΠΡΟΣ/KIBRIS • LATVIJA • LIETUVA • LUXEMBOURG • MAGYARORSZÁG • MALTA • NEDERLAND • ÖSTERREICH • POLSKA • PORTUGAL • ROMÂNIA • SLOVENIJA • SLOVENSKO • SUOMI/FINLAND • SVERIGE • UNITED KINGDOM • BELGIQUE/BELGIË • БЪЛГАРИЯ • ČESKÁ REPUBLIKA • DANMARK • DEUTSCHLAND • EESTI • ΕΛΛΑΔΑ • ESPAÑA • FRANCE • ÉIRE/IRELAND • ITALIA • ΚΥΠΡΟΣ/KIBRIS • LATVIJA • LIETUVA • LUXEMBOURG • MAGYARORSZÁG • MALTA • NEDERLAND • ÖSTERREICH • POLSKA • PORTUGAL • ROMÂNIA • SLOVENIJA • SLOVENSKO • SUOMI/FINLAND • SVERIGE • UNITED KINGDOM • BELGIQUE/BELGIË • БЪЛГАРИЯ • ČESKÁ REPUBLIKA • DANMARK • DEUTSCHLAND • EESTI • ΕΛΛΑΔΑ • ESPAÑA • FRANCE • ÉIRE/IRELAND • ITALIA • ΚΥΠΡΟΣ/KIBRIS • LATVIJA • LIETUVA • LUXEMBOURG • MAGYARORSZÁG • MALTA • NEDERLAND
    [Show full text]
  • Una Mirada a La Prensa Deportiva Nacional: El Fenómeno Marcelo Ríos
    UNIVERSIDAD DE CHILE FACULTAD DE CIENCIAS SOCIALES ESCUELA DE PERIODISMO Una Mirada a la Prensa Deportiva Nacional: El Fenómeno Marcelo Ríos. Rodrigo Andrés Miranda Sánchez. Memoria Para Optar al título de Periodista. Profesor Guía. Sergio Gilbert. Santiago, Marzo de 1999. I N D I C E Introducción 3 Orígenes Históricos 7 El Circuito ATP 9 Las Superficies del Tenis 12 Los Comienzos en Chile 15 Anita Lizana 18 Aparece Ayala 20 La Final contra Italia 24 La década de los ochenta 25 Zona de Promesas 28 El Repunte 32 Presente del Tenis Nacional 37 González - Massú 38 El Tenis en la Prensa (1993 - 1997) 41 Evolución 48 Una Mirada Revisionista 51 Conclusión: El Fenómeno Ríos 53 Anexos 62 Fuentes 90 pág. 2 I N T R O D U C C I O N Durante los últimos cinco años un nombre ha definido al tenis chileno. Y ese nombre no es otro que el de Marcelo Ríos. Desde sus primeros pasos en el profesionalismo, la figura del zurdo de Vitacura se ha convertido en uno de los ejes fundamentales de la prensa deportiva nacional, reactivando un segmento deportivo que estaba sumido en una de las crisis más grandes de los últimos años. Marcelo Ríos se ha transformado en una de las figuras noticiosas más importantes de nuestro país. Portada de diarios y revistas, ya sea deportivos o no; figura recurrente en los estelares de televisión; foco noticioso recurrente de noticieros; personaje de interés por su juego y personalidad ha contribuido enormemente a la difusión del deporte blanco en nuestro país que, por fin, cuenta con un ídolo que le permita recuperar el rumbo perdido.
    [Show full text]
  • KI Final Meeting Report Online Oxfordjuly 2014
    http://www.kidney-international.org meeting report & 2014 International Society of Nephrology The 2014 International Workshop on Alport Syndrome Jeffrey H. Miner1, Colin Baigent2, Frances Flinter3, Oliver Gross4, Parminder Judge2, Clifford E. Kashtan5, Sharon Lagas6, Judith Savige7, Dave Blatt8, Jie Ding9, Daniel P. Gale10, Julian P. Midgley11, Sue Povey12, Marco Prunotto13, Daniel Renault14, Jules Skelding15, A. Neil Turner16 and Susie Gear15 1Renal Division, Washington University School of Medicine, St Louis, Missouri, USA; 2Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, UK; 3Department of Clinical Genetics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 4Clinic of Nephrology and Rheumatology, University Medicine Goettingen, Goettingen, Germany; 5Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA; 6Alport Syndrome Foundation, Phoenix, Arizona, USA; 7Melbourne Health, The University of Melbourne, Parkville, Victoria, Australia; 8Alport Foundation of Australia, Valentine, New South Wales, Australia; 9Pediatric Department, Peking University First Hospital, Beijing, China; 10University College London-Center for Nephrology, London, UK; 11Department of Pediatrics, Alberta Children’s Hospital, Calgary, Alberta, Canada; 12Department of Genetics, Evolution and Environment, University College London, London, UK; 13Discovery Technology Department, Pharma Research and Early Development, Basel, Switzerland; 14Association for Information and Research on Genetic Renal Diseases (AIRG)-France, Paris, France; 15Alport UK, Tetbury, UK and 16Renal Medicine, Royal Infirmary, University of Edinburgh, Edinburgh, UK Alport syndrome, historically referred to as hereditary Kidney International advance online publication, 2 July 2014; glomerulonephritis with sensorineural deafness and anterior doi:10.1038/ki.2014.229 lenticonus, is a genetic disease of collagen a3a4a5(IV) KEYWORDS: ACE inhibitors; Alport syndrome; glomerulus; proteinuria resulting in renal failure.
    [Show full text]
  • Samp Ras, Contra Uno De Su Tierra
    42 LA VANGUARDIA DEPORTES MIÉRCOLES, 14ABRIL 1999 XLVIITROFEOCONDEDEGODÓ- IVOPEN SEAT CUADRO INDIVIDUALES;0] ras, y’* -2Ir1;! Samp contra . uii 1 : Sampras (EE.UU.) Pete Sampras — Vincent Spadea (EE.UU.) Vincenf Spadea fi Magnus Norman (SUE) • uno de su tierra Ándrew Ilie (AUS) Andrew lije Mark K. Goeliner (ALE) ] 6-4/6-3 Karim Alumi (MAR) Karim Alami Spadea, que nunca ha ganado al número 15.Magnus Gustafsson (SUE) 36/61/62 . 9. Albert Costa (ESP) Albert Costa uno, ha vencido este año a dos “top-ten”;1] Andrea Gaudenzi (ITA) 6-3/6-2 . Ronald Agenor (HA!) Fernando Vkente “1 . Fernando Vicente (ES!’) DAGOBERTO ESCORCIA co Magnus Norman, por 6-4 y 6-3. 6-4/7-5 Barcelona La tercera jornada del Trofeo Go Carlos Costa (FSP) Andrei Pavel dó también significará el debut del .i Andrel Povel (RUM) 6.3/6-7(7)/6-1 V enir de tan lejos, cruzar el segundo favorito, Carlos Moyá, an 8.Marcelo Ríos (CH!) Marcelo Ríos charco en un jet privado pa te el también español Germán Puen . ... Bye ••• 1 ra jugar un torneo en la su tes, un jugador que también debuta 3. Evgeni Kofelnikov (RUS) Evgeni Kafelnikov perficie que menos prefiere (la tie en el torneo, pero que no jugaba : . Bye1 rra), y encontrarse en su debut con uno del circuito ATP desde 1996. Franco Squillari (4kG) Fronco Squiliari tra un compatriota es algo que a Este año ha disputado los tres tor ““1 Pete Sampras, número uno del mun neos satélites que se juegan en Espa . ... JovierSánchez(ESP) .
    [Show full text]
  • Giornalino Tennis SET.2001
    NOTIZIARIO SOCIALE ANNO XXXVI SETTEMBRE 2001 UN TRIS TUTTO D’ORO L’unico titolo italiano della stagione 2001 conquistato dalla squadra femminile over 50 a Torre del Greco CA3MPIONATI DI SICILIA IBERICI GRANDI FA5VORITI SE8RIE A-1 I campioni ATTIVIT9À OPEN 1A1 TTIVITÀ AGONISTICA tornano TORNEO DI PAN1TEL4 LERIA RIA1PR4 E LA SAT alla Favorita ATTIVIT À1SO6 CIALE INDIRIZZO INTERNET : www.circolotennis.palermo.it • E- MAIL : [email protected] CAMPIONATI DI SICILIA Quanti campioni in gara nell’ Lts Cup Entry List DEL 18/8/2001 13) Federico Browne (Argentina) 14) Tomas Behrend (Germania) 1) Carlos Moya (Spagna) n. 16 15) Oscar Serrano (Spagna) 2) Albert Portas (Spagna) 25 16) Tomas Zib (Repubblica Ceca) 3) Tommy Robredo (Spagna) 39 17) Marc Lopez (Spagna) 4) Albert Costa (Spagna ) 40 18) Juan Albert Viloca (Spagna) 5) Andreas Vinciguerra (Svezia) 43 19) Marc Kevin Goellner (Germania) 6) Galo Blanco (Spagna) 44 20) Fernando Gonzales (Cile) 7) Franco Squillari (Argentina) 45 21) Nicolas Coutelot (Francia) 8) Jerome Golmard (Francia) 48 22) Noam Okun (Israele) 9) Andrea Gaudenzi (Italia) 56 23) Dimitry Tursunov (Russia) 10) Juan Balcells (Spagna) 59 24) Ronald Agenor (Haiti) 11) Fernando Vicente (Spagna) 68 25) Kevin Kim (Usa) 12) Iacobo Diaz (Spagna) 69 26) Marcos Ondruska (Sud Africa) 13) Felix Mantilla (Spagna) 72 27) Vincent Spadea (Usa) 14) Markus Hipfl (Austria) 76 28) Diego Hipperdinger (Spagna) 15) Josè Acasuso (Argentina) 77 29) Giorgio Galimberti (Italia) 16) David Nalbandian (Argentina) 81 30) Renzo Furlan (Italia)
    [Show full text]
  • Maddux, Braves Master Brewers
    CLASSIFIEDS/GO NBA 2D Inside Coming Wednesday UW sports 2D Black Wolf have Coverage of the Baseball 3D tough night Miller Lite 250 at vs. Goldeyes/2D Madison International Speedway ~>, Tuesday, July 27,1999* WISCONSIN STATE JOURNAL Sports Editor: Greg Sprout, (608) 252-6170 ANDY BAGGOT Corners take step forward COMMENTARY from the two, that experience will be vital. Edwards was the 25th overall pick and Vin- Inside Edwards, Vinson son the 47th in April's draft, in spite of the in- juries, which occurred during their senior ease into practices years in college. Yount proves They are expected to be the third and fourth cornerbacks behind starters Tyrone after foot injuries Williams and Craig Newsome, giving the force behind Packers four cover men for their multiple de- By Jason Wilde fensive back alignments — something the Sports reporter team didn't have last year. Vinson, who had surgery on a torn lig- the podium GREEN BAY — What Antuan Edwards ament in his left arch Dec. 29 and missed and Fred Vinson did Monday wasn't all that both post-draft minicamps, practiced in the Associated Press , First impressions, second much. morning session while Edwards sat out. thoughts and the third degree: But the fact that two rookie cornerbacks — "For my first day, I haven't done anything Phillips signs with 49ers both of whom are coming off foot injuries — Talk about your forehand-to- in the last 10 months, so it feels a little awk- ; the-forehead revelations. Who were able to participate in the first day of the ward being out there again," Vinson said.
    [Show full text]
  • 1995 La Vanguardia 13 Abril
    24 LA VANGUARDIA DEPORTES 13-14 ABRIL 1995 XLIII Trofeo Conde de Godó-III Open Renault Costa toma el relevo CUADRO DE INDIVIDUALES 1 Pete Sampras ífiFÍK// Pete Sampras ' i Bye Oliver Gross de Bruguera como David Whearon i Oliver Gross 1/6-6/2-6/3 Oliver Gross (ALE) 6/2-4/6-6/2 -^^"•••^ípyriffiffypilCToiftffiii mmmmmmmmimm.. Carlos Costa Ñ Carlos Costa (ESP) A# Olivier Delaitre (FRA) s 6/4-6/4 Carlos Costo favorito del público Paul Haarhuis (HOL) PaulHaorniuis 6/3-6/2 |W2j&/2 "Ü'^m^S^r" Thomas Muster Arresey Carbonell siguen tras eliminar a dosWC Jordi BurJkiTgW 4/6-7/6 (2J-6/2 W Thomas Muster QGeraldSolvesfflW Andrei Cherkasov 6/3-6/2 viejas glorias francesas, Forget y Leconte Andrei Cherkasov (RUS) m '»t*'! * ^^^^s^^a^ggggggreg^gg^^ysKjgj " j Javier Sánchez (ESP) XAVIER VENTURA pista. He tenido que jugarle alto y Javier Sánchez esperar a que fallara", dijo Costa. 6/1-1/6 6/0 I BARCELONA. - El premio para el ganador era ser IJnamJe^dwJ/fl^ Andrei Medvedev Carlos Costa sentía el siguiente rival de Pete Sampras. TEvgeni KafelnikovWsJ Evgeni Kafelnikov una piedra en su ca- Pero la eliminación del americano y Evgeni Kafelnikov .;•.• r. beza: la derrota que la de Sergi Bruguera lo cambia todo. HorstSkoffMÍW Richard Fromberg 6/2-6/7 7)-6/2 \\'V el holandés Paul Costas queda ahora convertido en el Richard Fromhen 1 Haarhuis le endosó, punto de mira sentimental de los í) Marcelo Ríos ,• .Í. a hace dos años, en Copa Davis, en un aficionados: es jugador del RCT : : partido que el catalán tenía ganado.
    [Show full text]
  • Manufacturing in Argentina, Brazil and Chile: Challenges and Opportunities
    Manufacturing in Argentina, Brazil and Chile: Challenges and Opportunities INDUSTRIAL MARKETS Contents Preface 1 Executive Summary 2 Introduction 6 Argentina: manufacturing investment and operations 21 Brazil: manufacturing investment and operations 36 Chile: manufacturing investment and operations 53 Conclusion 66 Manufacturing in Argentina, Brazil and Chile 1 Manufacturing in Argentina, Brazil and Chile: Challenges and Opportunities Something new and surprising is taking place in South America: in a region often marked by risk, uncertainty, and crisis, confidence is now rising rapidly. The economies of the region are clearly reviving. Overall growth rates are up. Currencies are appreciating. Yet inflation remains relatively low, and country risk ratings are falling. The revival is all the more surprising considering the depth of the crisis that sent an economic shockwave throughout the region in 2001, a crisis that brought the Argentine economy to its knees and which affected confidence, growth and currencies in Brazil, Chile and elsewhere. Global demand for agricultural products and commodities have helped drive the revival. But in many regional economies, domestic demand is also strong as personal incomes rise. And companies are responding to the atmosphere of renewed confidence with significant new direct investment commitments. What is more, these investments are increasingly in the manufacturing sector. After a decade or more when the majority of direct investment in the region was driven by privatization of the services sector, investment is now returning in force to manufacturing, increasing value added and creating new jobs. KPMG International recently asked a range of leading manufacturing companies to discuss the roots of this revival, in a series of lengthy one-to-one interviews with senior corporate strategists and CFOs.
    [Show full text]
  • Arianas %Riety~,?
    0 VNIVERSITY OF HAWAII UBRAR'( arianas %riety~,? Micronesia's Leading Newspaper Since 1972 \:,~ · ,_,, ' <:,, 3-yr limit bill clears House By Aldwin R. Fajardo they are allowed to seek re-em­ Variety News Staff ployment. A BILL that would require non­ But the Senate-approved ver­ resic.Jent workers, who have stayed sion c.Joes not say how long should in the Northern Marianas for three the workers stay out of the CNMI years to exit the islands for at least before they are allowed re-entry. six months before they can return House Speaker Diego T. for employment is now closer to Benavente earlier sai<l there has becoming law. to be a time frame as to how long This, after the House of Repre­ nonresident workers will not be sentatives yesterday passed an permitted to enter the Common- Gubernatorial teams do campaigning in preparation for Saturday's amended version of legislation . wealth again after they have election. Shown in this composite photo are (from top left, clockwise) that would set a three-year stay reached the three-year stay limit. a billboard for the Ada-Camacho tandem; Sens. Tom Ada and Lou limit for foreign labor. Benavente earlier expressed Leon Guerrero; Sen. Angel Santos and Joe Terlaje and Gov. Carl House action on Senate Bill I 1- Juan P. Tenorio intentions to press that foreign Gutierrez and Lt. Gov. Madeleine Z. Borda/lo. Photo by Eduardo C. Siguenza 71 was being awaited since the workers be obliged to stay out of Senate last month already passed it originated, fora vote on whether the Northern Marianas for a one­ Primary set for Saturday on final reading the measure in­ to accept or reject the House's year period.
    [Show full text]
  • June 3-4, 2021 Online
    IIA Estonia International Annual Conference 2021 Know the Future June 3-4, 2021 online Moderator Urmas Vaino Registration and additional information www.siseaudit.ee/Conference2021 We are celebrating the 20th anniversary of the Institute of Internal Auditors Estonia with our inter- national annual conference. On the first day of the annual conference, we are taking a courageous aim at the future. With the help of experts and practitioners of the business, we will discuss the possible future scenarios of Estonia up to year 2035. The second day of the conference offers an exciting exploratory trip on the trail of future internal auditors, where experts and opinion leaders from home and abroad will use their compasses to offer guidance. SCHEDULE I DAY – JUNE 3 11.00-12.40 I SESSION: “Wisdom belongs to the past, action to the present and happiness to the future.” (Chinese proverb) • Greetings • Inevitability to Change: Internal Audit and New Dimension – Karem Obeid, Executive Director of Internal Audit • Panel discussion: “The past is always tense, the future perfect.” (Zadie Smith) – Heikko Mäe, Management Board Member and Risk Manager of Coop Pank – Apo Oja, Management System Analyst of the Ministry of Defence – Piret Kustasson, Head of the Internal Audit Department in Omniva 12.40-13.30 Lunch break 13.30-15.00 II SESSION: “The best way to predict your future is to create it.” (Peter Drucker) • Estonia 2035 – Eili Lepik, Deputy Strategy Director at Strategy Unit of the Government Office – Tea Danilov, Head of the Foresight Centre – Sille
    [Show full text]